Compare Hilton Hotels Corporation Common Stock (HLT) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Immunovant Inc. Common Stock — how do they compare? Hilton Hotels Corporation Common Stock trades at $326.74 (market cap $72.76B), while Immunovant Inc. Common Stock trades at $30.36 (market cap $6.25B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 11.6× Immunovant Inc. Common Stock's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Immunovant Inc. Common Stock for 1 Days on average.
| HLT | IMVT | |
|---|---|---|
Market Cap | $72.76B | $6.25B |
Volume | 1,148,634 | 1,755,411 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $44.96 |
52-Week Low | $256.96 | $17.03 |
Typical Hold Time | 138 Days | 1 Days |
Enterprise Value | $85.78B | $5.35B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $327.48, up 2.18% today, reflecting strong momentum near its recent highs. The stock shows a bullish technical setup with consistent earnings beats in recent quarters and solid revenue growth, with 2025 revenue reaching $12.04 billion. Analyst sentiment is positive, with a consensus price target of $348.11 and no sell ratings among 49 analysts. Recent news highlights institutional buying and the upcoming Q3 2026 earnings report on October 27, 2026.
The outlook for HLT remains favorable, driven by robust travel demand, global portfolio expansion, and strong operational cash flow. Key risks include high debt levels, with a debt-to-asset ratio rising to 73.88% in 2025, and sensitivity to economic cycles. Upside potential hinges on continued execution and market share gains in high-growth regions like Asia, as noted in recent company reports.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
